| Literature DB >> 31953477 |
Luca Monzo1, Michele Schiariti1, Pietro Fedele Calvisi1, Silvio Bonfiglio2, Mitja Luštrek3, Paolo E Puddu4,5,6.
Abstract
Patient-reported outcomes (PROs) have been previously considered "soft" end-points because of the lack of association of the reported outcome to measurable biological parameters. The present study aimed to assess whether electrocardiographic measures are associated to PROs changes. We evaluated the association between heart rate (HR), QRS and QT/QTc durations and PROs, classified as "good" or "bad" according to the patients' overall feeling of health, in patients from the Chiron project. Twenty-four chronic heart failure (HF) patients were enrolled in the study (71% male, mean age 62.9 ± 9.4 years, 42% ischemic etiology, 15 NYHA class II and 9 class III) providing 1086 days of usable physiological recordings (4 hours/day). The mean HR was significantly higher in the "bad" than in the "good" PROs class (74.0 ± 6.4 bpm vs 68.0 ± 7.2 bpm; p < 0.001). Conversely, the ratio between movement and rest activities showed significantly higher values in "good" compared to "bad" PROs. We also found significantly longer QTc and QRS durations in patients with "bad" PROs compared to patients with "good" PROs. That in patients with mild to moderate HF, higher HR, wider QRS and longer QTc, as well as a reduced HR ratio between movement and rest, were associated with "bad" PROs is clinically noteworthy because the association of worse PROs with measurable variations of biological parameters may help physicians in evaluating PROs reliability itself and in their clinical decisions. Whether a timely intervention on these biological parameters may prevent adverse outcomes is important and deserves to be investigated in further studies.Entities:
Mesh:
Year: 2020 PMID: 31953477 PMCID: PMC6969136 DOI: 10.1038/s41598-019-57239-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics.
| Clinical characteristics | |
|---|---|
| Age, years | 62.9 ± 9.6 |
| Male, % | 72 |
| Body mass index, kg/m2 | 28.9 ± 3.9 |
| Current smokers, % | 28 |
| Chronic obstructive pulmonary disease, % | 32 |
| Coronary artery disease, % | 32 |
| Hypertension, % | 76 |
| Diabetes mellitus, % | 8 |
| Haemoglobin, g/L | 13.4 ± 1.6 |
| Sodium, mmol/L | 137.7 ± 4.1 |
| Potassium, mmol/L | 4.4 ± 0.4 |
| eGFR, mL/min/1.73 m2 | 70.8 ± 20.7 |
| Glucose, mg/dL | 106.6 ± 20.9 |
| C-reactive protein, mg/dL | 2.0 (1.0; 10.5) |
| Left ventricular mass index, gr/m2 | 128.7 ± 28.1 |
| Left ventricular ejection fraction, % | 34.7 ± 7.7 |
| Systolic blood pressure, mmHg | 122.5 ± 14.4 |
| Heart failure etiology, % | |
| - Ischemic | 42 |
| - Idiopathic | 25 |
| - Valvular | 8 |
| - Other aetiologies/cardiomyopathies | 25 |
| NYHA class, % | |
| - II | 64 |
| - III | 36 |
| Furosemide, % | 88 |
| ACEi or ARB, % | 80 |
| Mineralocorticoid antagonists, % | 48 |
| Betablocker, % | 84 |
| Digoxin, % | 16 |
| Devices, % | |
| - Implantable cardiac defibrillator | 24 |
| - Cardiac resynchronization therapy | 32 |
ACEi – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; eGFR – estimated glomerular filtration rate; NYHA – New York Heart Association.
Figure 1Average heart rate and the binomial (“good” and “bad”) classification of patient reported outcomes (PROs). Mid line and brackets represent mean ± SD.
Figure 2Average heart rate and the binomial (“good” and “bad”) classification of patient reported outcomes (PROs) during daily activities. (A) lying; (B) sitting; (C) moving. Mid line and brackets represent mean ± SD.
Figure 3Ratio between average heart rate during movement and rest activities and the binomial (“good” and “bad”) classification of patient reported outcomes (PROs). Mid line and brackets represent mean ± SD.
Figure 4(A) QRS, (B) QT and (C) corrected QT (QTc) intervals duration overall and during daily activities and the binomial (“good” and “bad”) classification of patient reported outcomes (PROs). Asterisks (*) located above the bars indicate a statistically significant p-value.